Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab

Aim: to describe the clinical characteristics and lung function changes among non-responders (NR) to Mepolizumab as per NICE criteria. Methods: A review of patients treated with Mepolizumab in Nottingham. ACQ6, lung function tests (FeNO, FOT, spirometry) were performed and blood taken for eosinophil count at baseline and 12 months. Results: Forty patients completed a year of treatment (65% female; mean age 48±12) with a mean of 27(+15) years since diagnosis and 7.5(+5) exacerbations/year before the treatment. Sixteen (40%) were classified as NR and had similar demographic and clinical features to responders (R) except for years of asthma symptoms (34vs22, p=0.016). Median FEV1 did not improve significantly in the NR group (n=13) although 6 patients demonstrated an improvement in FEV1 and 5 patients a reduction Conclusion: Significant changes in important biomarkers, symptom burden, and exacerbation rate may be seen and considered in severe eosinophilic asthma patients who do not respond to Mepolizumab as per NICE criteria.